332 Genetic testing for cyp2c19*2 but not for pon-1 qq carrier status predicts high on-clopidogrel platelet reactivity in patients undergoing percutaneous coronary interventions

Influence of the paraoxonase‐1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta‐analysis

“…To study the potential impact of platelet reactivity data missing from three studies totalling 1544 patients, a sensitivity analysis was performed with the following extreme hypotheses: the mean difference and standard deviation in platelet assay results between PON1‐192QQ and 192QQ + RR subjects in each missing study was set to the highest possible standardized mean difference, knowing that the differences were reported as statistically non‐significant in each of the three missing studies. Assuming that all differences were positive, this corresponded to standardized mean differences of 0.42 (0.00; 0.85), 0.32 (0.00; 0.63) and 0.11 (0.00; 0.22), for the studies of 88 [36], 157 [34] and 1299 patients [35], respectively. Following this extreme hypothesis, the pooled standardized mean difference would be 0.12 (−0.01; 0.25) ( P = 0.07).…”

“…1. There were 11 449 patients enrolled in the 17 selected studies [12,[14][15][16][17][25][26][27][28][29][30][31][32][33][34][35][36], which were all published in 2011 or 2012, most data being derived from existing cohorts. Details of the 17 studies are shown in Table 1.…”

“…As shown in the flow chart in Fig. 1, summarized data could not be abstracted from 10 studies, corresponding to five published papers [16,[26][27][28]32] and four conference abstracts [33][34][35][36]. All summarized data required to compute a 2 · 2 table for MACE were kindly provided by the corresponding author of the published papers.…”

“…All summarized data required to compute a 2 · 2 table for MACE were kindly provided by the corresponding author of the published papers. Similarly, the means and standard deviation of platelet function assay results could not be retrieved from the publications of eight studies [16,27,28,[33][34][35][36]. In three instances of studies presented at conferences but PON1-Q192R, MACE and platelet reactivity 1245 not yet published, summarized data could not be obtained from the authors (n = 1575) [34][35][36].…”